Post
Happy_shanky
🚨 $LLY — ELI LILLY’S NEXT OBESITY DRUG SHOWS STRONG RESULTS
ELI LILLY’S EXPERIMENTAL ELORALINTIDE, WHEN COMBINED WITH ZEPBOUND, PRODUCED AN AVERAGE 23.3% WEIGHT LOSS OVER AROUND 11 MONTHS.
THAT COMPARES WITH 14.8% FOR ZEPBOUND ALONE IN PATIENTS WITH TYPE 2 DIABETES.
⚠️ HOWEVER, 11%–27% OF PATIENTS STOPPED THE COMBINATION DUE TO SIDE EFFECTS, KEEPING TOLERABILITY AS AN IMPORTANT CONSIDERATION.
LILLY EXPECTS TO MOVE ELORALINTIDE INTO LATE-STAGE TRIALS LATER THIS YEAR.
#DailyOrbit
Disclaimer: OKX Orbit content is provided for informational purposes only. Learn more
Replies
No comments yet. Be the first to reply!
Trending crypto
BTC/USDTBitcoin
$83,390.3-0.01%
ETH/USDTEthereum
$2,676.27+0.00%
ZEC/USDTZcash
$1,405.79-0.03%
Today’s market buzz
1#RateHikeDelayedJobsNext
Hot
2#BTCInflowETHOutflow
3#USTreasuryYieldsClimb